<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Biopharmaceuticals on FinanClub</title>
    <link>https://finan.club/tags/biopharmaceuticals/</link>
    <description>Recent content in Biopharmaceuticals on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Thu, 29 Feb 2024 09:04:06 +0000</lastBuildDate><atom:link href="https://finan.club/tags/biopharmaceuticals/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>TGTX</title>
      <link>https://finan.club/us/tgtx/</link>
      <pubDate>Thu, 29 Feb 2024 09:04:06 +0000</pubDate>
      
      <guid>https://finan.club/us/tgtx/</guid>
      <description>score:174
Chances: TG Therapeutics stock soared after meeting sales expectations for multiple sclerosis treatment Company announced strong U.S. net revenue for BRIUMVI and extended exclusivity of ublituximab through newly issued patents Positive earnings and revenue surprises for the quarter ended December 2023 Risks: Stock price sensitivity to institutional ownership Lack of right combination for a likely earnings beat in upcoming report Score:174 chances characters count - risks characters count = 174</description>
    </item>
    
  </channel>
</rss>
